Curcumin improves diabetes mellitus‑associated cerebral infarction by increasing the expression of GLUT1 and GLUT3

  • Authors:
    • Mingyu Xia
    • Zankai Ye
    • Yanfeng Shi
    • Libo Zhou
    • Yang Hua
  • View Affiliations

  • Published online on: November 15, 2017     https://doi.org/10.3892/mmr.2017.8085
  • Pages: 1963-1969
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Curcumin is characterized by anti‑inflammatory, anti‑oxidative, antiviral, antifibrotic, anticoagulation and glucose regulatory functions. However, whether it is protective in diabetes mellitus‑associated cerebral infarction remains to be fully elucidated. In the present study, it was demonstrated for the first time, to the best of our knowledge, that curcumin markedly improved neurological deficits, cerebral infarct volume and brain edema rate following middle cerebral artery occlusion (MCAO) surgery. It was also shown that the expression levels of glucose transporter (GLUT)1 and GLUT3 were reduced in the MCAO group. However, following curcumin treatment, the levels of GLUT1 and GLUT3 were markedly increased. In addition, curcumin markedly decreased cell apoptosis, indicating an anti‑apoptotic role of curcumin in the brain. To further evaluate whether curcumin prevented cell apoptosis by modulating the expression of GLUT1 and GLUT3, small interfering RNAs targeting GLUT1 and GLUT3 were selected. It was found that the knockdown of GLUT1 and GLUT3 inhibited the abundance of GLUT1, GLUT3 and B‑cell lymphoma 2, even following incubation with curcumin. These data showed that curcumin protected brain cells from apoptosis and cerebral infarction, predominantly by upregulating GLUT1 and GLUT3.

References

1 

Zhao L and Hu FX: α-Lipoic acid treatment of aged type 2 diabetes mellitus complicated with acute cerebral infarction. Eur Rev Med Pharmacol Sci. 18:3715–3719. 2014.

2 

Liu X, Zhou Y, Wang J, Liu X, Yang C, Li J, Chen S and Wu S: Effect of central obesity on the events of new-onset cerebral infarction among type 2 diabetes mellitus patients. Zhonghua Liu Xing Bing Xue Za Zhi. 35:390–392. 2014.(In Chinese).

3 

Inagaki K, Nagao M and Oikawa S: Internal medicine and neurological diseases: Progress in diagnosis and treatment. Topics: II neurological diseases related to diabetes mellitus; 2. Cerebral infarction, coma, hypoglycemia. Nihon Naika Gakkai Zasshi. 101:2180–2187. 2012.(In Japanese). View Article : Google Scholar

4 

Cambon H, Derouesne C, Yelnik A, Duyckaerts C and Hauw JJ: Effect of diabetes mellitus and blood glucose on the size of cerebral infarction and causes of death. Neuropathological study of 77 cases of infarction in the sylvian artery area. Rev Neurol (Paris). 147:727–734. 1991.

5 

Du L, Ma J and Zhang X: Higher serum uric acid may contribute to cerebral infarction in patients with type 2 diabetes mellitus: A meta-analysis. J Mol Neurosci. 61:25–31. 2017. View Article : Google Scholar

6 

Ichikawa H, Shimizu Y, Kuriki A, Murakami H, Mukai M and Kawamura M: The brainstem is at high risk for recurrent noncardioembolic cerebral infarction in association with diabetes mellitus: A hospital-based study. Eur Neurol. 67:26–32. 2012. View Article : Google Scholar

7 

Kawamura T, Umemura T, Kanai A, Nagashima M, Nakamura N, Uno T, Nakayama M, Sano T, Hamada Y, Nakamura J and Hotta N: Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. Metabolism. 55:461–466. 2006. View Article : Google Scholar

8 

Long Y, Zhan Q, Yuan M, Duan X, Zhou J, Lu J, Li Z, Yu F, Zhou X, Yang Q and Xia J: The expression of microRNA-223 and FAM5C in cerebral infarction patients with diabetes mellitus. Cardiovasc Toxicol. 17:42–48. 2017. View Article : Google Scholar

9 

Petzold S, Kapellen T, Siekmeyer M, Hirsch W, Bartelt H, Siekmeyer W and Kiess W: Acute cerebral infarction and extra pontine myelinolysis in children with new onset type 1 diabetes mellitus. Pediatr Diabetes. 12:513–517. 2011. View Article : Google Scholar

10 

Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD and Song YQ: Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: A network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 18:1199–1206. 2016. View Article : Google Scholar

11 

Mittal N, Mittal R, Kumar H and Medhi B: Sodium glucose co-transporter 2 inhibitors for glycemic control in type 2 diabetes mellitus: Quality of reporting of randomized controlled trials. Perspect Clin Res. 7:21–27. 2016. View Article : Google Scholar :

12 

Nunez DJ, Yao X, Lin J, Walker A, Zuo P, Webster L, Krug-Gourley S, Zamek-Gliszczynski MJ, Gillmor DS and Johnson SL: Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: Double-blind randomized trials with type 2 diabetes subjects taking metformin. Diabetes Obes Metab. 18:654–662. 2016. View Article : Google Scholar

13 

Ohki T, Isogawa A, Toda N and Tagawa K: Effectiveness of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin Drug Investig. 36:313–319. 2016. View Article : Google Scholar

14 

Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, Ahn YB, Kim ES, Moon SD, Kim MJ and Ko SH: Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 11:e01657032016. View Article : Google Scholar :

15 

Singh AK and Singh R: Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence. Indian J Endocrinol Metab. 20:245–253. 2016. View Article : Google Scholar :

16 

Tang H, Cui W, Li D, Wang T, Zhang J, Zhai S and Song Y: Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 19:142–147. 2017. View Article : Google Scholar

17 

Yabe D, Iwasaki M, Kuwata H, Haraguchi T, Hamamoto Y, Kurose T, Sumita K, Yamazato H, Kanada S and Seino Y: Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab. 19:739–743. 2017. View Article : Google Scholar :

18 

Aziz MT, El Ibrashy IN, Mikhailidis DP, Rezq AM, Wassef MA, Fouad HH, Ahmed HH, Sabry DA, Shawky HM and Hussein RE: Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy. Diabetol Metab Syndr. 5:132013. View Article : Google Scholar :

19 

Margina D, Gradinaru D, Manda G, Neagoe I and Ilie M: Membranar effects exerted in vitro by polyphenols-quercetin, epigallocatechin gallate and curcumin-on HUVEC and Jurkat cells, relevant for diabetes mellitus. Food Chem Toxicol. 61:86–93. 2013. View Article : Google Scholar

20 

Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K and Kitahara M: Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem. 53:959–963. 2005. View Article : Google Scholar

21 

Bulboacă AD, Bolboacă S and Suci S: Protective effect of curcumin in fructose-induced metabolic syndrome and in streptozotocin-induced diabetes in rats. Iran J Basic Med Sci. 19:585–593. 2016.

22 

Castro CN, Tabarrozzi Barcala AE, Winnewisser J, Gimeno ML, Noguerol Antunica M, Liberman AC, Paz DA, Dewey RA and Perone MJ: Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes. Clin Exp Immunol. 177:149–160. 2014. View Article : Google Scholar :

23 

Li G, Xu X, Wang D, Wang J, Wang Y and Yu J: Microglial activation during acute cerebral infarction in the presence of diabetes mellitus. Neurol Sci. 32:1075–1079. 2011. View Article : Google Scholar

24 

Zhang B, Wang D, Ji TF, Shi L and Yu JL: Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model. Oncotarget. 8:17347–17359. 2017.

25 

Kobayashi S: Progress in diagnosis of and therapy for cerebral infarction in patients with diabetes mellitus. Nihon Naika Gakkai Zasshi. 93:1532–1538. 2004.(In Japanese). View Article : Google Scholar

26 

Chiu J, Khan ZA, Farhangkhoee H and Chakrabarti S: Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition. 25:964–972. 2009. View Article : Google Scholar

27 

Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C and Jirawatnotai S: Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 35:2121–2127. 2012. View Article : Google Scholar :

28 

El-Azab MF, Attia FM and El-Mowafy AM: Novel role of curcumin combined with bone marrow transplantation in reversing experimental diabetes: Effects on pancreatic islet regeneration, oxidative stress and inflammatory cytokines. Eur J Pharmacol. 658:41–48. 2011. View Article : Google Scholar

Related Articles

Journal Cover

January 2018
Volume 17 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xia, M., Ye, Z., Shi, Y., Zhou, L., & Hua, Y. (2018). Curcumin improves diabetes mellitus‑associated cerebral infarction by increasing the expression of GLUT1 and GLUT3. Molecular Medicine Reports, 17, 1963-1969. https://doi.org/10.3892/mmr.2017.8085
MLA
Xia, M., Ye, Z., Shi, Y., Zhou, L., Hua, Y."Curcumin improves diabetes mellitus‑associated cerebral infarction by increasing the expression of GLUT1 and GLUT3". Molecular Medicine Reports 17.1 (2018): 1963-1969.
Chicago
Xia, M., Ye, Z., Shi, Y., Zhou, L., Hua, Y."Curcumin improves diabetes mellitus‑associated cerebral infarction by increasing the expression of GLUT1 and GLUT3". Molecular Medicine Reports 17, no. 1 (2018): 1963-1969. https://doi.org/10.3892/mmr.2017.8085